{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:59:57Z","timestamp":1771851597417,"version":"3.50.1"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.2169\/internalmedicine.1268-18","type":"journal-article","created":{"date-parts":[[2018,11,18]],"date-time":"2018-11-18T22:33:09Z","timestamp":1542580389000},"page":"693-697","source":"Crossref","is-referenced-by-count":14,"title":["Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma"],"prefix":"10.2169","volume":"58","author":[{"given":"Yuka","family":"Mishima","sequence":"first","affiliation":[{"name":"Respiratory Medicine, Ome Municipal General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukaishi","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, Ome Municipal General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Inase","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Tokyo Medical and Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Isogai","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Ome Municipal General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44: 51-60, 2016.","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107: 1055-1058, 2016.","DOI":"10.1111\/cas.12961"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46: 86-88, 2016.","DOI":"10.1093\/jjco\/hyv158"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 6: 53-66, 2012.","DOI":"10.4137\/CMO.S5855"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Zeng MF, Chen L, Ye HY, et al. Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy. Medicine (Baltimore) 96: e8426, 2017.","DOI":"10.1097\/MD.0000000000008426"},{"key":"6","doi-asserted-by":"crossref","first-page":"e000217","DOI":"10.1136\/esmoopen-2017-000217","volume":"2","author":"M Kastrisiou","year":"2017","unstructured":"6. Kastrisiou M, Kostadima FL, Kefas A, et al. Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. ESMO Open 2: e000217, 2017.","journal-title":"ESMO Open","ISSN":"https:\/\/id.crossref.org\/issn\/2059-7029","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015.","DOI":"10.1056\/NEJMoa1504627"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.","DOI":"10.1056\/NEJMoa1507643"},{"key":"9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"9. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19: 82-92, 2016.","journal-title":"Pituitary","ISSN":"https:\/\/id.crossref.org\/issn\/1386-341X","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Corsello SM, Barnabel A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98: 1361-1375, 2013.","DOI":"10.1210\/jc.2012-4075"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ishikawa M, Oashi K. Case of hypophysitis caused by nivolumab. J Dermatol 44: 109-110, 2017.","DOI":"10.1111\/1346-8138.13437"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Honegger J, Schlaffer S, Menzel C, et al. Diagnosis of primary hypophysitis in Germany. J Clin Endocrinol Metab 100: 3841-3849, 2015.","DOI":"10.1210\/jc.2015-2152"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tanaka R, Fujisawa Y, Maruyama H, et al. Nivolumab-induced thyroid dysfunction. Jpn J Clin Oncol 46: 575-579, 2016.","DOI":"10.1093\/jjco\/hyw036"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Orlov S, Salari F, Kashat L, Walfish PG. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 100: 1738-1741, 2015.","DOI":"10.1210\/jc.2014-4560"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Okano Y, Satoh T, Horiguchi K, et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J 63: 905-912, 2016.","DOI":"10.1507\/endocrj.EJ16-0161"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Marlier J, Cocquyt V, Brochez L, Van Belle S, Kruse V. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine 47: 878-883, 2014.","DOI":"10.1007\/s12020-014-0199-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691-2697, 2012.","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Johnson DB, Friedman DL, Berry E, et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immnol Res 3: 464-469, 2015.","DOI":"10.1158\/2326-6066.CIR-14-0217"},{"key":"19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","volume":"115","author":"K Sato","year":"2018","unstructured":"19. Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115: 71-74, 2018.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/5\/58_1268-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T05:36:10Z","timestamp":1551504970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/5\/58_1268-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1268-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}